Tibial Fracture
0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
TevaIsrael - Petach Tikva
1 programautologous mesenchymal stem cells implantationPHASE_1_21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Tevaautologous mesenchymal stem cells implantation
BonesupportCERAMENT|G
Clinical Trials (2)
Total enrollment: 225 patients across 2 trials
Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal Tibial Fractures
Start: Apr 2009Est. completion: Apr 201124 patients
Phase 1/2Completed
Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures
Start: Feb 2017Est. completion: Jul 2021201 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.